Time trends and inter-hospital variation in treatment and axillary staging of patients with ductal carcinoma in situ of the breast in the era of screening in Southern Netherlands

Breast

Volumn 23, Issue 1, 2014, Pages 63-68

  Van Steenbergen, L N ^a   Voogd, A C ^a,b   Roukema, J A ^c,f   Louwman, W J ^a   Duijm, L E M ^e   Coebergh, J W W ^a,d   Van de Poll Franse, L V ^a,f  

^a Eindhoven Cancer Registry   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c Microvida Laboratory for Medical Microbiology and Immunology   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^f TILBURG UNIVERSITY   (Netherlands)

Author keywords

Axillary staging; DCIS; Screening; Treatment; Variation

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; FEMALE; HEALTH CARE UTILIZATION; HISTOPATHOLOGY; HOSPITAL SERVICE; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MIDDLE AGED; NETHERLANDS; PARTIAL MASTECTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SENTINEL LYMPH NODE BIOPSY; TIME TO TREATMENT; TREATMENT PLANNING; TREND STUDY;

AXILLARY STAGING; DCIS; SCREENING; TREATMENT; VARIATION;

AGED; AXILLA; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; GUIDELINE ADHERENCE; HOSPITALS; HUMANS; LOGISTIC MODELS; LYMPH NODE EXCISION; LYMPH NODES; MASTECTOMY; MASTECTOMY, SEGMENTAL; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NETHERLANDS; PRACTICE GUIDELINES AS TOPIC; RADIOTHERAPY, ADJUVANT; SENTINEL LYMPH NODE BIOPSY;

EID: 84890878027     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.11.001     Document Type: Article

References (37)

1. Welch H.G., Black W.C. Using autopsy series to estimate the disease "reservoir" for ductal carcinoma in situ of the breast: how much more breast cancer can we find?. Ann Intern Med 1997, 127:1023-1028.
2. van Steenbergen L.N., Voogd A.C., Roukema J.A., Louwman W.J., Duijm L.E., Coebergh J.W. Screening caused rising incidence rates of ductal carcinoma in situ of the breast. Breast Cancer Res Treat 2009, 115:181-183.
3. Ernster V.L., Barclay J., Kerlikowske K., Wilkie H., Ballard-Barbash R. Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med 2000, 160:953-958.
4. Silverstein M.J., Barth A., Poller D.N., Gierson E.D., Colburn W.J., Waisman J.R., et al. Ten-year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast. Eur J Cancer 1995, 31A:1425-1427.
5. Silverstein M.J., Cohlan B.F., Gierson E.D., Furmanski M., Gamagami P., Colburn W.J., et al. Duct carcinoma in situ: 227 cases without microinvasion. Eur J Cancer 1992, 28:630-634.
6. National clinical practice guidelines. [accessed 24.03.13]. http://www.oncoline.nl.
7. Julien J.P., Bijker N., Fentiman I.S., Peterse L.J., Delledonne V., Rouanet P., et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet 2000, 355:528-533.
8. Houghton J., George W.D., Cuzick J., Duggan C., Fentiman I.S., Spittle M. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 2003, 362:95-102.
9. Fisher B., Land S., Mamounas E., Dignam J., Fisher E.R., Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol 2001, 28:400-418.
10. Bijker N., Meijnen P., Peterse J.L., Bogaerts J., van Hoorebeeck I., Julien J.P., et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853-a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. JClin Oncol 2006, 24:3381-3387.
11. Baxter N.N., Virnig B.A., Durham S.B., Tuttle T.M. Trends in the treatment of ductal carcinoma in situ of the breast. JNatl Cancer Inst 2004, 96:443-448.
12. Rakovitch E., Pignol J.P., Chartier C., Hanna W., Kahn H., Wong J., et al. The management of ductal carcinoma in situ of the breast: a screened population-based analysis. Breast Cancer Res Treat 2007, 101:335-347.
13. Schouten van der Velden A.P., Van Dijck J.A., Wobbes T. Variations in treatment of ductal carcinoma in situ of the breast: a population-based study in the East Netherlands. Eur J Surg Oncol 2007, 33:424-429.
14. Fritz A., Percy C., Jack A., Shanmugaratnam K., Sobin L., Parkin D., et al. International classification of diseases for oncology 2000, World Health Organisation, Geneva. 3rd ed.
15. UICC TNM classification of malignant tumours 2002, Wiley-Liss, New York. 6th ed.
16. Comprehensive Cancer Centre Netherlands/Comprehensive Cancer Centre South. [accessed 17.12.12]. http://www.cijfersoverkanker.nl.
17. Schouten L.J., Hoppener P., van den Brandt P.A., Knottnerus J.A., Jager J.J. Completeness of cancer registration in Limburg, The Netherlands. Int J Epidemiol 1993, 22:369-376.
18. Stichting Bevolkingsonderzoek Borstkanker Zuid Jaarverslag 2006 Stichting Bevolkingsonderzoek Borstkanker Zuid 2006.
19. Otten J.D., Karssemeijer N., Hendriks J.H., Groenewoud J.H., Fracheboud J., Verbeek A.L., et al. Effect of recall rate on earlier screen detection of breast cancers based on the Dutch performance indicators. JNatl Cancer Inst 2005, 97:748-754.
20. Kricker A., Armstrong B. Surgery and outcomes of ductal carcinoma in situ of the breast: a population-based study in Australia. Eur J Cancer 2004, 40:2396-2402.
21. Porembka M.R., Abraham R.L., Sefko J.A., Deshpande A.D., Jeffe D.B., Margenthaler J.A. Factors associated with lymph node assessment in ductal carcinoma in situ: analysis of 1988-2002 seer data. Ann Surg Oncol 2008, 15:2709-2719.
22. Verkooijen H.M., Fioretta G., De Wolf C., Vlastos G., Kurtz J., Borisch B., et al. Management of women with ductal carcinoma in situ of the breast: a population-based study. Ann Oncol 2002, 13:1236-1245.
23. Evans A.J., Pinder S., Ellis I.O., Sibbering M., Elston C.W., Poller D.N., et al. Screening-detected and symptomatic ductal carcinoma in situ: mammographic features with pathologic correlation. Radiology 1994, 191:237-240.
24. van Steenbergen L.N., van de Poll-Franse L.V., Wouters M.W., Jansen-Landheer M.L., Coebergh J.W., Struikmans H., et al. Variation in management of early breast cancer in The Netherlands, 2003-2006. Eur J Surg Oncol 2010, 36(Suppl.1):S36-S43.
25. Siesling S., van de Poll-Franse L.V., Jobsen J.J., Repelaer van Driel O.J., Voogd A.C. Explanatory factors for variation in the use of breast conserving surgery and radiotherapy in The Netherlands, 1990-2001. Breast 2007 Dec, 16(6):606-614.
26. Arbeitsgemeinschaft Gynäkologische Onkologie (AGO). http://www.ago-online.de/de/fuer-mediziner/leitlinien/mamma/maerz-2012/.
27. Association of Breast Surgery at BASO 2009 Surgical guidelines for the management of breast cancer. Eur J Surg Oncol 2009, 35(Suppl.1):1-22.
28. Staley H., McCallum I., Bruce J. Postoperative tamoxifen for ductal carcinoma in situ. Cochrane Database Syst Rev 2012, 10:CD007847.
29. Wallis M.G., Clements K., Kearins O., Ball G., Macartney J., Lawrence G.M. The effect of DCIS grade on rate, type and time to recurrence after 15 years of follow-up of screen-detected DCIS. Br J Cancer 2012, 106:1611-1617.
30. Ververs J.M., Roumen R.M., Vingerhoets A.J., Vreugdenhil G., Coebergh J.W., Crommelin M.A., et al. Risk, severity and predictors of physical and psychological morbidity after axillary lymph node dissection for breast cancer. Eur J Cancer 2001, 37:991-999.
31. Ansari B., Ogston S.A., Purdie C.A., Adamson D.J., Brown D.C., Thompson A.M. Meta-analysis of sentinel node biopsy in ductal carcinoma in situ of the breast. Br J Surg 2008, 95:547-554.
32. Shapiro-Wright H.M., Julian T.B. Sentinel lymph node biopsy and management of the axilla in ductal carcinoma in situ. JNatl Cancer Inst Monogr 2010, 2010:145-149.
33. Timmers J.M., den Heeten G.J., Adang E.M., Otten J.D., Verbeek A.L., Broeders M.J. Dutch digital breast cancer screening: implications for breast cancer care. Eur J Public Health 2011, 22:925-929.
34. Nederend J., Duijm L.E., Louwman M.W., Groenewoud J.H., Donkers-van Rossum A.B., Voogd A.C. Impact of transition from analog screening mammography to digital screening mammography on screening outcome in The Netherlands: a population-based study. Ann Oncol 2012, 12:3098-3103.
35. Jorgensen K.J., Keen J.D., Gotzsche P.C. Is mammographic screening justifiable considering its substantial overdiagnosis rate and minor effect on mortality?. Radiology 2011, 260:621-627.
36. de Gelder R., Heijnsdijk E.A., van Ravesteyn N.T., Fracheboud J., Draisma G., de Koning H.J. Interpreting overdiagnosis estimates in population-based mammography screening. Epidemiol Rev 2011, 33:111-121.
37. Kopans D.B., Smith R.A., Duffy S.W. Mammographic screening and "overdiagnosis". Radiology 2011, 260:616-620.